Durvalumab With or Without Tremelimumab in Combination With Chemoradiotherapy in Patients With Limited-Stage SCLC: Results from the Phase 1 CLOVER Study

Byoung Chul Cho, Myung-Ju Ahn, Makoto Nishio, Haruyasu Murakami, Dong Wan-Kim, Sang-We Kim, Sana D. Karam, Ana Estival, Chia-Chi Lin, Jose Manuel Trigo, Rosa Alvarez, Chih Liang Wang, Mingchao Xie, Sonia Iyer, Jon Armstrong, Priti Chugh, Haiyi Jiang, Julie E. Bauman

Open source

DOI: 10.1016/j.jtocrr.2025.100884
Published: 2025-10
Container: JTO Clinical and Research Reports
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.jtocrr.2025.100884,
  title = {Durvalumab With or Without Tremelimumab in Combination With Chemoradiotherapy in Patients With Limited-Stage SCLC: Results from the Phase 1 CLOVER Study},
  author = {Byoung Chul Cho and Myung-Ju Ahn and Makoto Nishio and Haruyasu Murakami and Dong Wan-Kim and Sang-We Kim and Sana D. Karam and Ana Estival and Chia-Chi Lin and Jose Manuel Trigo and Rosa Alvarez and Chih Liang Wang and Mingchao Xie and Sonia Iyer and Jon Armstrong and Priti Chugh and Haiyi Jiang and Julie E. Bauman},
  year = {2025},
  journal = {JTO Clinical and Research Reports},
  doi = {10.1016/j.jtocrr.2025.100884},
  url = {https://doi.org/10.1016/j.jtocrr.2025.100884}
}

RIS

TY  - JOUR
TI  - Durvalumab With or Without Tremelimumab in Combination With Chemoradiotherapy in Patients With Limited-Stage SCLC: Results from the Phase 1 CLOVER Study
AU  - Byoung Chul Cho
AU  - Myung-Ju Ahn
AU  - Makoto Nishio
AU  - Haruyasu Murakami
AU  - Dong Wan-Kim
AU  - Sang-We Kim
AU  - Sana D. Karam
AU  - Ana Estival
AU  - Chia-Chi Lin
AU  - Jose Manuel Trigo
AU  - Rosa Alvarez
AU  - Chih Liang Wang
AU  - Mingchao Xie
AU  - Sonia Iyer
AU  - Jon Armstrong
AU  - Priti Chugh
AU  - Haiyi Jiang
AU  - Julie E. Bauman
PY  - 2025
JO  - JTO Clinical and Research Reports
DO  - 10.1016/j.jtocrr.2025.100884
UR  - https://doi.org/10.1016/j.jtocrr.2025.100884
ER  -

APA

Cho, B. C., Ahn, M., Nishio, M., Murakami, H., Wan-Kim, D., Kim, S., Karam, S. D., Estival, A., Lin, C., Trigo, J. M., Alvarez, R., Wang, C. L., Xie, M., Iyer, S., Armstrong, J., Chugh, P., Jiang, H., & Bauman, J. E. (2025). Durvalumab With or Without Tremelimumab in Combination With Chemoradiotherapy in Patients With Limited-Stage SCLC: Results from the Phase 1 CLOVER Study. JTO Clinical and Research Reports. https://doi.org/10.1016/j.jtocrr.2025.100884

Source records

crossref · retrieved 2026-09-26T21:47:24.106Z